Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.
Clinical trial details
A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours.
Identifier
CBT307-1
Sponsor
CRESCENDO BIOLOGICS
Principal Investigator
JOAN CARLES GALCERAN
Service
Oncology
Study details
Tumor type: PROSTATE
Stage: Advanced
Main Investigational Agent : Biespecific antibodies
Phase: I
Randomization: Non-randomized
Molecular details
Biomarker: PSMA pos
Biomarker criteria: Mandatory
Prescreening: Central
Additional study population requirements: Not applicable
